Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Severe Diabetic Macular Oedema With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser When the Thickness of the Central Retina Goes Below 400 Microns: Pragmatic Randomised Equivalence Trial

NCT06985706 is registered in ClinicalTrials.gov with Belfast Health and Social Care Trust as lead sponsor.

NCT NCT06985706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06985706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Severe Diabetic Macular Oedema With Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser When the Thickness of the Central Retina Goes Below 400 Microns: Pragmatic Randomised Equivalence Trial
Lead sponsor
Belfast Health and Social Care Trust
Phase
Phase 3
Overall status
Recruiting
Start date
May 19, 2025
Completion date
November 30, 2028
Enrollment
264 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

severe diabetic macular oedema